We are analyzing https://link.springer.com/article/10.1007/s00262-008-0493-6.

Title:
HLA typing demands for peptide-based anti-cancer vaccine | Cancer Immunology, Immunotherapy
Description:
Immunological treatment of cancer has made some very promising advances during the last years. Anti-cancer vaccination using peptides or peptide-pulsed dendritic cells and adoptive transfer of in vitro generated, epitope-specific T cells depend on a well-fitting interaction of HLA molecule and epitope. Accurate HLA-typing is a key factor for successful anti-cancer vaccination. No comprehensive data and no suggestion exist on the HLA-typing in this setting. We performed a systematic review of PubMed analyzing HLA-typing data in cancer vaccination trials over the last 4 years (2004–2007). Then, using the SYFPEITHI database, we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding epitopes. Finally, high-resolution typing [by sequence-specific primers (SSP)] data of a HLA-A*02 or HLA-A*24 positive population in Berlin, Germany, were analyzed. Forty-five cancer vaccination trials with 764 patients were included. Eighteen studies were performed in the USA, 13 in Europe, 12 in Asia (mainly Japan), and two in Australia. Most common diseases targeted were melanoma, prostate cancer, colorectal cancer, renal cell cancer, and breast cancer. The trials tested protocols using peptide plus adjuvants without DC or protocols using peptide-pulsed DC. In 38 trials (84%) HLA-A2 positive patients were vaccinated, in 11 studies (24%) HLA-A24 positive patients were vaccinated. Nineteen studies with 291 patients (38%) presented the HLA type as four-digit code (high-resolution), 26 studies with 473 patients (62%) presented the HLA-type in a low-resolution code. The method of HLA determination was given in six out of 45 trials (13%). Using the SYFPEITHI database we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding tumor antigen-derived epitopes for binding to HLA-A*0203. While the epitopes had a binding score of 17–28 for HLA-A*0201, the score for binding to HLA-A*0203 was zero in seven out of eight tested peptides. Only for one peptide the score was eight. Finally, we analyzed high-resolution data of HLA-A*02 and HLA-A*24 positive patients in Berlin, Germany. We found the HLA-A*0201 allele and HLA-A*2402 allele in 95%, respectively. HLA-A*0201 and HLA-A*2402 are most commonly used for peptide based vaccine in cancer. Data on HLA-typing given in the included cancer vaccine manuscripts are fractional. Only 13% report the method of HLA typing and most HLA types are given as low-resolution code. Looking at the binding of specific peptides to both the alleles, it is important to perform high-resolution typing. Further suggestions for immunogenetic laboratories and clinical tumor immunologists regarding HLA-typing for cancer vaccine trials and adoptive T cell transfer approaches are discussed.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, article, google, scholar, pubmed, cas, patients, peptide, vaccination, cells, dendritic, hlaa, melanoma, hla, clin, vaccine, cell, immunother, phase, prostate, clinical, res, peptides, immunol, metastatic, binding, antigen, data, study, immunization, oncol, trial, itoh, immunotherapy, colorectal, vaccinated, class, carcinoma, advanced, iii, yamada, typing, nagorsen, immunological, peptidepulsed, trials, renal, specific, human, responses,

Topics {✒️}

p53-peptide-pulsed dendritic cells peptide-based anti-cancer vaccine peptide-loaded dendritic-cell vaccination hla-a24-restricted ctl epitope month download article/chapter adoptive-cell-transfer therapy progenitor-derived dendritic cells mhc-peptide specificity peptide-pulsed dendritic cells multiple peptide vaccines dendritic cell-based immunotherapy monocyte/dendritic cell precursors dendritic cell vaccines recombinant vaccinia-virus small-cell lung cancer melanoma peptide-pulsed cd34 patient-oriented peptide vaccination specific t-cell responses t-cell epitope mapping successful anti-cancer vaccination ny-eso-1-expressing cancer perform high-resolution typing specific tumor-reactive ctl carcinoembryonic antigen-derived article cancer immunology low-dose interleukin-2 administered prostate-specific antigen recurrence strong human cd8+ peptide based vaccine hla-a2 positive patients hla-a24+ hrpc patients dendritic cells loaded renal cell carcinoma full article pdf hla-a24 positive patients dendritic cells pulsed analyzed high-resolution data renal cell cancer peptide-pulsed dc dendritic cells modified metastatic colorectal carcinoma cancer vaccines ny-eso-1 peptide privacy choices/manage cookies dendritic cell immunizations article nagorsen melanoma reactive ctl immature dendritic cells ny-eso-1 antigen anti-cancer vaccination

Questions {❓}

Chang CC, Campoli M, Ferrone S (2004) HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:HLA typing demands for peptide-based anti-cancer vaccine
         description:Immunological treatment of cancer has made some very promising advances during the last years. Anti-cancer vaccination using peptides or peptide-pulsed dendritic cells and adoptive transfer of in vitro generated, epitope-specific T cells depend on a well-fitting interaction of HLA molecule and epitope. Accurate HLA-typing is a key factor for successful anti-cancer vaccination. No comprehensive data and no suggestion exist on the HLA-typing in this setting. We performed a systematic review of PubMed analyzing HLA-typing data in cancer vaccination trials over the last 4 years (2004–2007). Then, using the SYFPEITHI database, we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding epitopes. Finally, high-resolution typing [by sequence-specific primers (SSP)] data of a HLA-A*02 or HLA-A*24 positive population in Berlin, Germany, were analyzed. Forty-five cancer vaccination trials with 764 patients were included. Eighteen studies were performed in the USA, 13 in Europe, 12 in Asia (mainly Japan), and two in Australia. Most common diseases targeted were melanoma, prostate cancer, colorectal cancer, renal cell cancer, and breast cancer. The trials tested protocols using peptide plus adjuvants without DC or protocols using peptide-pulsed DC. In 38 trials (84%) HLA-A2 positive patients were vaccinated, in 11 studies (24%) HLA-A24 positive patients were vaccinated. Nineteen studies with 291 patients (38%) presented the HLA type as four-digit code (high-resolution), 26 studies with 473 patients (62%) presented the HLA-type in a low-resolution code. The method of HLA determination was given in six out of 45 trials (13%). Using the SYFPEITHI database we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding tumor antigen-derived epitopes for binding to HLA-A*0203. While the epitopes had a binding score of 17–28 for HLA-A*0201, the score for binding to HLA-A*0203 was zero in seven out of eight tested peptides. Only for one peptide the score was eight. Finally, we analyzed high-resolution data of HLA-A*02 and HLA-A*24 positive patients in Berlin, Germany. We found the HLA-A*0201 allele and HLA-A*2402 allele in 95%, respectively. HLA-A*0201 and HLA-A*2402 are most commonly used for peptide based vaccine in cancer. Data on HLA-typing given in the included cancer vaccine manuscripts are fractional. Only 13% report the method of HLA typing and most HLA types are given as low-resolution code. Looking at the binding of specific peptides to both the alleles, it is important to perform high-resolution typing. Further suggestions for immunogenetic laboratories and clinical tumor immunologists regarding HLA-typing for cancer vaccine trials and adoptive T cell transfer approaches are discussed.
         datePublished:2008-03-04T00:00:00Z
         dateModified:2008-03-04T00:00:00Z
         pageStart:1903
         pageEnd:1910
         sameAs:https://doi.org/10.1007/s00262-008-0493-6
         keywords:
            HLA
            Peptide
            Vaccine
            Cancer
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:57
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Dirk Nagorsen
               affiliation:
                     name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
                     address:
                        name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
                     name:Medizinische Klinik III Charité, Campus Benjamin Franklin
                     address:
                        name:Immunogenetics Lab, Medizinische Klinik III Charité, Campus Benjamin Franklin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Eckhard Thiel
               affiliation:
                     name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
                     address:
                        name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:HLA typing demands for peptide-based anti-cancer vaccine
      description:Immunological treatment of cancer has made some very promising advances during the last years. Anti-cancer vaccination using peptides or peptide-pulsed dendritic cells and adoptive transfer of in vitro generated, epitope-specific T cells depend on a well-fitting interaction of HLA molecule and epitope. Accurate HLA-typing is a key factor for successful anti-cancer vaccination. No comprehensive data and no suggestion exist on the HLA-typing in this setting. We performed a systematic review of PubMed analyzing HLA-typing data in cancer vaccination trials over the last 4 years (2004–2007). Then, using the SYFPEITHI database, we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding epitopes. Finally, high-resolution typing [by sequence-specific primers (SSP)] data of a HLA-A*02 or HLA-A*24 positive population in Berlin, Germany, were analyzed. Forty-five cancer vaccination trials with 764 patients were included. Eighteen studies were performed in the USA, 13 in Europe, 12 in Asia (mainly Japan), and two in Australia. Most common diseases targeted were melanoma, prostate cancer, colorectal cancer, renal cell cancer, and breast cancer. The trials tested protocols using peptide plus adjuvants without DC or protocols using peptide-pulsed DC. In 38 trials (84%) HLA-A2 positive patients were vaccinated, in 11 studies (24%) HLA-A24 positive patients were vaccinated. Nineteen studies with 291 patients (38%) presented the HLA type as four-digit code (high-resolution), 26 studies with 473 patients (62%) presented the HLA-type in a low-resolution code. The method of HLA determination was given in six out of 45 trials (13%). Using the SYFPEITHI database we calculated the peptide binding prediction of the eight most often used HLA-A*0201 binding tumor antigen-derived epitopes for binding to HLA-A*0203. While the epitopes had a binding score of 17–28 for HLA-A*0201, the score for binding to HLA-A*0203 was zero in seven out of eight tested peptides. Only for one peptide the score was eight. Finally, we analyzed high-resolution data of HLA-A*02 and HLA-A*24 positive patients in Berlin, Germany. We found the HLA-A*0201 allele and HLA-A*2402 allele in 95%, respectively. HLA-A*0201 and HLA-A*2402 are most commonly used for peptide based vaccine in cancer. Data on HLA-typing given in the included cancer vaccine manuscripts are fractional. Only 13% report the method of HLA typing and most HLA types are given as low-resolution code. Looking at the binding of specific peptides to both the alleles, it is important to perform high-resolution typing. Further suggestions for immunogenetic laboratories and clinical tumor immunologists regarding HLA-typing for cancer vaccine trials and adoptive T cell transfer approaches are discussed.
      datePublished:2008-03-04T00:00:00Z
      dateModified:2008-03-04T00:00:00Z
      pageStart:1903
      pageEnd:1910
      sameAs:https://doi.org/10.1007/s00262-008-0493-6
      keywords:
         HLA
         Peptide
         Vaccine
         Cancer
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:57
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Dirk Nagorsen
            affiliation:
                  name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
                  address:
                     name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
                  name:Medizinische Klinik III Charité, Campus Benjamin Franklin
                  address:
                     name:Immunogenetics Lab, Medizinische Klinik III Charité, Campus Benjamin Franklin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Eckhard Thiel
            affiliation:
                  name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
                  address:
                     name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:57
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
      address:
         name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
         type:PostalAddress
      name:Medizinische Klinik III Charité, Campus Benjamin Franklin
      address:
         name:Immunogenetics Lab, Medizinische Klinik III Charité, Campus Benjamin Franklin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
      address:
         name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Dirk Nagorsen
      affiliation:
            name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
            address:
               name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
               type:PostalAddress
            type:Organization
            name:Medizinische Klinik III Charité, Campus Benjamin Franklin
            address:
               name:Immunogenetics Lab, Medizinische Klinik III Charité, Campus Benjamin Franklin, Berlin, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Eckhard Thiel
      affiliation:
            name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
            address:
               name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
      name:Immunogenetics Lab, Medizinische Klinik III Charité, Campus Benjamin Franklin, Berlin, Germany
      name:Medical Department of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(194)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.92s.

LINK . SPRINGER . COM {}